Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer

Background. Currently, perioperative chemotherapy is the standard treatment option for resectable gastric cancer (GC ) at stages higher than T1. Preoperative chemotherapy was shown do not adversely affect the course of the postoperative period in gastric cancer patients. However, approximately 60 %...

Full description

Bibliographic Details
Main Authors: A. V. Avgustinovich, S. G. Afanasyev, A. Yu. Dobrodeev, M. Yu. Volkov, D. N. Kostromitsky, L. V. Spirina, O. V. Cheremisina
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2022-03-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/2023
_version_ 1797875749094424576
author A. V. Avgustinovich
S. G. Afanasyev
A. Yu. Dobrodeev
M. Yu. Volkov
D. N. Kostromitsky
L. V. Spirina
O. V. Cheremisina
author_facet A. V. Avgustinovich
S. G. Afanasyev
A. Yu. Dobrodeev
M. Yu. Volkov
D. N. Kostromitsky
L. V. Spirina
O. V. Cheremisina
author_sort A. V. Avgustinovich
collection DOAJ
description Background. Currently, perioperative chemotherapy is the standard treatment option for resectable gastric cancer (GC ) at stages higher than T1. Preoperative chemotherapy was shown do not adversely affect the course of the postoperative period in gastric cancer patients. However, approximately 60 % of radically operated patients complete adjuvant chemotherapy. In this regard, the problem arises of postponing all courses of chemotherapy for operable gastric cancer to the preoperative period.The purpose of the study was to analyze short-term efficacy and toxicity of total neoadjuvant chemotherapy with FLOT regimen in patients with resectable gastric cancer.Material and Methods. Since 2020, the Research Cancer Institute of Tomsk National Research Medical Center has been conducting a pilot study, which included 25 patients with resectable gastric cancer (T2–4N0–2M0) who received 8 cycles of neoadjuvant chemotherapy with FLOT regimen followed by radical surgery (gastrectomy or distal subtotal resection of the stomach).Results. Preoperative chemotherapy was completed in 25 (100 %) patients. Side effects that occurred during chemotherapy did not require cancellation or interruption of treatment and reduction in the initial dose of drugs. The most common adverse events were emetogenic reactions (92 %), peripheral neuropathy (60 %), and neutropenia (48 %). All patients had no greater than grade II toxicity, which was reversed with standard maintenance therapy. Radical surgeries were performed 6 weeks after completion of chemotherapy cycle 8. There were no significant postoperative complications (grade III or higher according to the Clavien–Dindo scale) and deaths. The histological examination revealed pathological response of TG R2–3 grade in 21 (84%) patients. Downstaging in both T and N categories was found in 13 (52%) patients.Conclusion. Eight cycles of total neoadjuvant chemotherapy for resectable gastric cancer demonstrates high efficacy, moderate toxicity, and do not adversely affect the course of the perioperative period.
first_indexed 2024-04-10T01:52:33Z
format Article
id doaj.art-c0b54ca61dc54a4a95f2ed0d4e0fd68d
institution Directory Open Access Journal
issn 1814-4861
2312-3168
language Russian
last_indexed 2024-04-10T01:52:33Z
publishDate 2022-03-01
publisher Russian Academy of Sciences, Tomsk National Research Medical Center
record_format Article
series Сибирский онкологический журнал
spelling doaj.art-c0b54ca61dc54a4a95f2ed0d4e0fd68d2023-03-13T09:05:55ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682022-03-01211111910.21294/1814-4861-2022-21-1-11-19956Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancerA. V. Avgustinovich0S. G. Afanasyev1A. Yu. Dobrodeev2M. Yu. Volkov3D. N. Kostromitsky4L. V. Spirina5O. V. Cheremisina6Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукBackground. Currently, perioperative chemotherapy is the standard treatment option for resectable gastric cancer (GC ) at stages higher than T1. Preoperative chemotherapy was shown do not adversely affect the course of the postoperative period in gastric cancer patients. However, approximately 60 % of radically operated patients complete adjuvant chemotherapy. In this regard, the problem arises of postponing all courses of chemotherapy for operable gastric cancer to the preoperative period.The purpose of the study was to analyze short-term efficacy and toxicity of total neoadjuvant chemotherapy with FLOT regimen in patients with resectable gastric cancer.Material and Methods. Since 2020, the Research Cancer Institute of Tomsk National Research Medical Center has been conducting a pilot study, which included 25 patients with resectable gastric cancer (T2–4N0–2M0) who received 8 cycles of neoadjuvant chemotherapy with FLOT regimen followed by radical surgery (gastrectomy or distal subtotal resection of the stomach).Results. Preoperative chemotherapy was completed in 25 (100 %) patients. Side effects that occurred during chemotherapy did not require cancellation or interruption of treatment and reduction in the initial dose of drugs. The most common adverse events were emetogenic reactions (92 %), peripheral neuropathy (60 %), and neutropenia (48 %). All patients had no greater than grade II toxicity, which was reversed with standard maintenance therapy. Radical surgeries were performed 6 weeks after completion of chemotherapy cycle 8. There were no significant postoperative complications (grade III or higher according to the Clavien–Dindo scale) and deaths. The histological examination revealed pathological response of TG R2–3 grade in 21 (84%) patients. Downstaging in both T and N categories was found in 13 (52%) patients.Conclusion. Eight cycles of total neoadjuvant chemotherapy for resectable gastric cancer demonstrates high efficacy, moderate toxicity, and do not adversely affect the course of the perioperative period.https://www.siboncoj.ru/jour/article/view/2023резектабельный рак желудкакомбинированное лечениетотальная неоадъювантная химиотерапиятоксичностьнепосредственная эффективность
spellingShingle A. V. Avgustinovich
S. G. Afanasyev
A. Yu. Dobrodeev
M. Yu. Volkov
D. N. Kostromitsky
L. V. Spirina
O. V. Cheremisina
Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
Сибирский онкологический журнал
резектабельный рак желудка
комбинированное лечение
тотальная неоадъювантная химиотерапия
токсичность
непосредственная эффективность
title Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
title_full Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
title_fullStr Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
title_full_unstemmed Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
title_short Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
title_sort short term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer
topic резектабельный рак желудка
комбинированное лечение
тотальная неоадъювантная химиотерапия
токсичность
непосредственная эффективность
url https://www.siboncoj.ru/jour/article/view/2023
work_keys_str_mv AT avavgustinovich shorttermefficacyandtoxicityoftotalneoadjuvantchemotherapyinpatientswithresectablegastriccancer
AT sgafanasyev shorttermefficacyandtoxicityoftotalneoadjuvantchemotherapyinpatientswithresectablegastriccancer
AT ayudobrodeev shorttermefficacyandtoxicityoftotalneoadjuvantchemotherapyinpatientswithresectablegastriccancer
AT myuvolkov shorttermefficacyandtoxicityoftotalneoadjuvantchemotherapyinpatientswithresectablegastriccancer
AT dnkostromitsky shorttermefficacyandtoxicityoftotalneoadjuvantchemotherapyinpatientswithresectablegastriccancer
AT lvspirina shorttermefficacyandtoxicityoftotalneoadjuvantchemotherapyinpatientswithresectablegastriccancer
AT ovcheremisina shorttermefficacyandtoxicityoftotalneoadjuvantchemotherapyinpatientswithresectablegastriccancer